NATURES SUNSHINE PRODUCTS INC (NATR): Results of Operations and Financial Condition
NATURES SUNSHINE PRODUCTS INC (NATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 3 natrq22026earningsrelease.htm EX-99.1 Document Nature's Sunshine Reports Second Quarter 2026 Results Net Sales up 2% to $117.0 million, Gross Profit Margin up 194 Basis Points to 73.7% LEHI, Utah – August 6, 2026 – Nature’s Sunshine Products, Inc. (Nasdaq: NATR) ("Natur
How this was made
The 30-second read
Why it matters
Traders can update forward revenue and EBITDA expectations using the revised FY2026 ranges, while also weighing Q2 gross margin expansion and segment commentary (Asia growth, North America digital sales).
Market read
The primary tradable element is the explicit guidance reduction for FY2026 net sales and adjusted EBITDA, framed by stronger USD and China softness, alongside Q2 margin improvement.
What to watch
The filing notes other income swung due to foreign exchange effects and that GAAP net income fell partly due to the prior purchase of noncontrolling interests, which can distort headline earnings quality versus operating performance.
Background
SEC 8-K includes Q2 2026 operating results and an updated full-year outlook, plus an officer/director compensation item.
Ticker impact
Nature’s Sunshine reports Q2 results and cuts FY2026 net sales and adjusted EBITDA guidance due to a stronger U.S. dollar and China softness.
Likely near-term volatility around the guidance cut, with support if investors focus on margin expansion and digital/Asia growth details.
The filing includes specific Q2 datapoints (net sales, gross margin, GAAP EPS, adjusted EBITDA) and explicit FY2026 guidance ranges revised lower, which are direct inputs to valuation and forward estimates.
Market effects
Provides a read-through for natural supplements direct-selling and digital subscription models, especially sensitivity to FX and China demand.
Highlights Asia Pacific growth and North America digital acceleration, while flagging China softness as a key drag.
FX-driven guidance sensitivity may influence how investors model cross-border revenue for similar consumer health names.
Counterpoint
Investors may underreact to the guidance cut if they believe margin expansion and digital auto-ship adoption will offset China weakness over the back half of 2026.
Key entities
- companyNature’s Sunshine Products, Inc.
Nasdaq-listed herbal and nutritional supplements manufacturer and marketer that reported Q2 results and revised FY2026 guidance in an 8-K.
- executiveKen Romanzi
CEO quoted on Q2 performance drivers and the start of investments under the Vision for Growth plan.
